These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 12053315)

  • 21. Catheter closure of the persistent foramen ovale: mid-term results in 162 patients.
    Beitzke A; Schuchlenz H; Gamillscheg A; Stein JI; Wendelin G
    J Interv Cardiol; 2001 Apr; 14(2):223-9. PubMed ID: 12053310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial experience with the novel patent foramen ovale occlusion device Nit-Occlud® in patients with stroke or transient ischemic attack.
    Steinberg DH; Bertog SC; Momberger J; Franke J; Hofmann I; Renkhoff K; Joy S; Vaskelyte L; Sievert H
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1262-7. PubMed ID: 24948394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Flatstent versus the conventional umbrella devices in the percutaneous closure of patent foramen ovale.
    Aral M; Mullen M
    Catheter Cardiovasc Interv; 2015 May; 85(6):1058-65. PubMed ID: 25413379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medium-term results of transcatheter closure of patent foramen ovale (PFO) with Amplatzer PFO and Cribriform occluders.
    Białkowski J; Wawrzyńczyk M; Karwot B; Fiszer R; Knop M; Szkutnik M
    Kardiol Pol; 2012; 70(11):1142-6. PubMed ID: 23180522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients.
    Krumsdorf U; Ostermayer S; Billinger K; Trepels T; Zadan E; Horvath K; Sievert H
    J Am Coll Cardiol; 2004 Jan; 43(2):302-9. PubMed ID: 14736453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interventional closure of patent foramen ovale with Nit-occlud® device in prevention of recurrent neurologic events-Long-term results.
    Araszkiewicz A; Sławek S; Trojnarska O; Lesiak M; Grygier M
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):159-164. PubMed ID: 29068141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patent foramen ovale closure following cryptogenic stroke or transient ischaemic attack: Long-term follow-up of 301 cases.
    Mirzaali M; Dooley M; Wynne D; Cooter N; Lee L; Haworth P; Saha R; Gainsborough N; Hildick-Smith D
    Catheter Cardiovasc Interv; 2015 Nov; 86(6):1078-84. PubMed ID: 26105198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermediate and long-term results of transcatheter closure of patent foramen ovale using the amplatzer patent foramen ovale occluder: one case of pulmonary embolism irrespective of patent foramen ovale closure.
    Yoon JH; Kim JS; Lee DH; Shim EJ; Lee SY; Min KS; Cho DJ; Lee HR
    Korean Circ J; 2011 Jul; 41(7):356-62. PubMed ID: 21860636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgical patent foramen ovale closure for prevention of paradoxical embolism-related cerebrovascular ischemic events.
    Dearani JA; Ugurlu BS; Danielson GK; Daly RC; McGregor CG; Mullany CJ; Puga FJ; Orszulak TA; Anderson BJ; Brown RD; Schaff HV
    Circulation; 1999 Nov; 100(19 Suppl):II171-5. PubMed ID: 10567299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Transcatheter closure of atrial septal defects in adults. Practicality and safety of four different closure systems used in 102 patients].
    La Rosée K; Krause D; Becker M; Beuckelmann DJ; Deutsch HJ; Höpp HW
    Dtsch Med Wochenschr; 2001 Sep; 126(38):1030-6. PubMed ID: 11565056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Causes of recurrent focal neurologic events after transcatheter closure of patent foramen ovale with the CardioSEAL septal occluder.
    Kutty S; Brown K; Asnes JD; Rhodes JF; Latson LA
    Am J Cardiol; 2008 May; 101(10):1487-92. PubMed ID: 18471463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long term follow up after percutaneous closure of PFO in 357 patients with paradoxical embolism: Difference in occlusion systems and influence of atrial septum aneurysm.
    von Bardeleben RS; Richter C; Otto J; Himmrich L; Schnabel R; Kampmann C; Rupprecht HJ; Marx J; Hommel G; Münzel T; Horstick G
    Int J Cardiol; 2009 May; 134(1):33-41. PubMed ID: 18715659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta-analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Michel P
    Int J Cardiol; 2013 Oct; 169(2):101-5. PubMed ID: 24041984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla
    Neuser J; Akin M; Bavendiek U; Kempf T; Bauersachs J; Widder JD
    BMC Cardiovasc Disord; 2016 Nov; 16(1):217. PubMed ID: 27832757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study design of the CLOSURE I Trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale.
    Furlan AJ; Reisman M; Massaro J; Mauri L; Adams H; Albers GW; Felberg R; Herrmann H; Kar S; Landzberg M; Raizner A; Wechsler L;
    Stroke; 2010 Dec; 41(12):2872-83. PubMed ID: 21051670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Percutaneous patent foramen ovale closure: outcomes with the Premere and Amplatzer devices.
    Bissessor N; Wong AW; Hourigan LA; Jayasinghe RS; Scalia GS; Burstow DJ; Griffiths LR; Savage M; Walters DL
    Cardiovasc Revasc Med; 2011; 12(3):164-169. PubMed ID: 21640934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Follow-Up After Closure of Patent Foramen Ovale in Patients With Cryptogenic Embolism.
    Wintzer-Wehekind J; Alperi A; Houde C; Côté JM; Asmarats L; Côté M; Rodés-Cabau J
    J Am Coll Cardiol; 2019 Jan; 73(3):278-287. PubMed ID: 30678757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke.
    Windecker S; Wahl A; Nedeltchev K; Arnold M; Schwerzmann M; Seiler C; Mattle HP; Meier B
    J Am Coll Cardiol; 2004 Aug; 44(4):750-8. PubMed ID: 15312853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial experience with a transcatheter septal closure system for secondary stroke prevention in patients with interatrial septal defects.
    Silverman IE; Kiernan FJ; Kelsey AM; Brakoniecki JJ; Kazi FA; Dougherty JE; Boden WE; McKay RG
    Conn Med; 2003 Mar; 67(3):135-44. PubMed ID: 12687787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk and fate of residual interatrial shunting after transcatheter closure of patent foramen ovale: a long term follow up study.
    Hammerstingl C; Bauriedel B; Stüsser C; Momcilovic D; Tuleta I; Nickenig G; Skowasch D
    Eur J Med Res; 2011 Jan; 16(1):13-9. PubMed ID: 21345765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.